{"id":665870,"date":"2023-08-31T21:04:01","date_gmt":"2023-08-31T21:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=665870"},"modified":"2023-08-31T21:04:01","modified_gmt":"2023-08-31T21:04:01","slug":"propulsion-of-xlinked-retinitis-pigmentosa-clinical-trial-pipeline-as-novel-and-extensive-5-therapies-likely-to-enter-in-the-domain-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/propulsion-of-xlinked-retinitis-pigmentosa-clinical-trial-pipeline-as-novel-and-extensive-5-therapies-likely-to-enter-in-the-domain-delveinsight_665870.html","title":{"rendered":"Propulsion of X-Linked Retinitis Pigmentosa Clinical Trial Pipeline as Novel and Extensive 5+ Therapies Likely to Enter in the Domain | DelveInsight"},"content":{"rendered":"<p style=\"text-align: justify;\">(Albany, United States) As per DelveInsight&rsquo;s assessment, globally, the X-Linked Retinitis Pigmentosa Pipeline constitutes 5+ key companies continuously working towards developing 5+ X-Linked Retinitis Pigmentosa Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the X-Linked Retinitis Pigmentosa Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, X-Linked Retinitis Pigmentosa NDA approvals (if any), and product development activities comprising the technology, X-Linked Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To explore more information on the latest breakthroughs in the X-Linked Retinitis Pigmentosa Pipeline treatment landscape of the report, click here @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">X-Linked Retinitis Pigmentosa Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the X-Linked Retinitis Pigmentosa Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s X-Linked Retinitis Pigmentosa Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.<\/li>\n<li>The leading companies working in the X-Linked Retinitis Pigmentosa market include Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research &amp; Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.<\/li>\n<li>PromisingX-Linked Retinitis Pigmentosa Pipeline Therapies in the various stages of development include Genetic: AAV5-RPGR, AAV2\/5-RPGR, FT-002, Docosahexaenoic Acid OR corn\/Soy Oil placebo, and others.<\/li>\n<li>On May 2023, Frontera Therapeutics announced a study of Early Phase 1 clinical trials for FT-002. A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).<\/li>\n<li>On June 2023, MeiraGTx UK II Ltd announced a study of phase 3 clinical trials for Genetic: AAV5-RPGR. A clinical trial of AAV5-RPGR vector for patients with X-linked retinitis pigmentosa (XLRP).<\/li>\n<li>On August 2023, Janssen Pharmaceutical K.K. announced a study of Phase 3 clinical trials for AAV5-hRKp.RPGR. The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. Retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>X-Linked Retinitis Pigmentosa Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">X-linked Retinitis Pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information, refer to the detailed X-Linked Retinitis Pigmentosa Unmet Needs, click here for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>X-Linked Retinitis Pigmentosa Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>BIIB 112 (NSR-RPGR): Biogen<\/li>\n<li>4D-125: 4 D Molecular Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>X-Linked Retinitis Pigmentosa Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 5+ key companies which are developing the therapies for X-linked Retinitis Pigmentosa. The companies which have their X-linked Retinitis Pigmentosa drug candidates in the mid to advanced stage, Phase II\/III include, Biogen and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in X-Linked Retinitis Pigmentosa Ongoing Clinical Trial Analysis and Medications, Click here for more details @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">X-Linked Retinitis Pigmentosa Segmentation<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>X-Linked Retinitis Pigmentosa Drugs and Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Genetic: AAV5-RPGR: MeiraGTx UK II Ltd<\/li>\n<li>FT-002: Frontera Therapeutics<\/li>\n<li>Docosahexaenoic Acid OR Corn\/Soy Oil Placebo: Retina Foundation of the Southwest\/ DSM Nutritional Products Inc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>X-Linked Retinitis Pigmentosa Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by Stage and Product Type<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration<\/li>\n<li>Assessment by Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Companies in the X-Linked Retinitis Pigmentosa Therapeutics Market include-<\/strong><\/p>\n<p style=\"text-align: justify;\">Biogen, 4D Molecular Therapeutics, Applied Genetics Technology Corporation, Janssen Research &amp; Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for drugs for the X-Linked Retinitis Pigmentosa Pipeline, Click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">X-Linked Retinitis Pigmentosa Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the X-Linked Retinitis Pigmentosa Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Companies- Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, Janssen Research &amp; Development LLC, MeiraGTx UK II Ltd, Syne Qua Non Limited, Bionical Emas, Frontera Therapeutics, DSM Nutritional Products Inc., and others.<\/li>\n<li>Therapies- Genetic: AAV5-RPGR, AAV2\/5-RPGR, FT-002, Docosahexaenoic Acid OR corn\/Soy Oil placebo, and others.<\/li>\n<li>Segmentation: Product Type, Molecule Type, Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Got Queries? Find out the related information on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">X-Linked Retinitis Pigmentosa Merger and acquisitions, Licensing Activities<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>X-linked Retinitis Pigmentosa: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>X-linked Retinitis Pigmentosa &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>X-linked Retinitis Pigmentosa Collaboration Deals<\/li>\n<li>Late Stage Products (Phase II\/III)<\/li>\n<li>BIIB 112 (NSR-RPGR): Biogen<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase I\/II)<\/li>\n<li>4D-125: 4 D Molecular Therapeutics<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Pre-clinical and Discovery Stage Products<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>X-linked Retinitis Pigmentosa Key Companies<\/li>\n<li>X-linked Retinitis Pigmentosa Key Products<\/li>\n<li>X-linked Retinitis Pigmentosa- Unmet Needs<\/li>\n<li>X-linked Retinitis Pigmentosa- Market Drivers and Barriers<\/li>\n<li>X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion<\/li>\n<li>X-linked Retinitis Pigmentosa Analyst Views<\/li>\n<li>X-linked Retinitis Pigmentosa Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=propulsion-of-xlinked-retinitis-pigmentosa-clinical-trial-pipeline-as-novel-and-extensive-5-therapies-likely-to-enter-in-the-domain-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=propulsion-of-xlinked-retinitis-pigmentosa-clinical-trial-pipeline-as-novel-and-extensive-5-therapies-likely-to-enter-in-the-domain-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Albany, United States) As per DelveInsight&rsquo;s assessment, globally, the X-Linked Retinitis Pigmentosa Pipeline constitutes 5+ key companies continuously working towards developing 5+ X-Linked Retinitis Pigmentosa Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/propulsion-of-xlinked-retinitis-pigmentosa-clinical-trial-pipeline-as-novel-and-extensive-5-therapies-likely-to-enter-in-the-domain-delveinsight_665870.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-665870","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=665870"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665870\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=665870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=665870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=665870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}